Chemical Epigenetics, Epigenetics Drug Discovery

in Freiburg

Our focus is the synthesis of enzyme inhibitors and assay development for the determination of the activity of histone modifying enzymes and their inhibitors. We develop and optimize potent and selective inhibitors of epigenetic enzymes as potential drug candidates and tools for biological research.
http://jungm.de

Technologies

Synthesis, In-vitro assay development and screening (enzyme inhibition), detection of enzyme activity in biological matrices (cells, tissue, blood), pharmacokinetic analyses (HPLC from biological samples)

Publications

Ten selected publications.

1. A Non-Isotopic Assay for Histone Deacetylase Activity. K. Hoffmann, G. Brosch,
P. Loidl, M. Jung; Nucleic Acids Res. 27 (1999), 2057-2058.
2. Identification of selective inhibitors of NAD+-dependent deacetylases using phenotypic screening in yeast. M. Hirao, J. Posakony, M. Nelson, H. Hruby, M. Jung, J. A. Simon, A. Bedalov; J. Biol. Chem. 278 (2003), 52773-52783.

(…)

Contact

Prof. Dr. Manfred Jung
Institut für Pharmazeutische Wissenschaften
Epigenetics Drug Discovery Group
Albert-Ludwigs-Universität
Freiburg



Email: